Welcome to Arrien Pharmaceuticals

Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer, and Neurodegenerative diseases. The Arrien Pharmaceuticals successfully applied and applying its proprietary platform FIELDS technology and discovered a pipeline of uniquely positioned clinical stage programs for future treatment of Cancer, Psoriasis, Rheumatoid Arthritis (RA), and Parkinson's Diseases.

Arrien Pharmaceuticals FIELDS technology is a Fragment-Based Drug Design typically involves empirical and structural data input assisting our Medicinal Chemists in early phase of lead-to-drug-lead design process. Arrien Pharmaceuticals cost-competent approach rapidly aid our scientific team in selecting pre-clinical candidate ready compounds.

Arrien Pharmaceuticals most advanced program ARN-6039 successfully completed Phase 1 clinical trials late Q4 2016. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. A Phase 2 clinical POC studies for Psoriasis (oral and topical), Multiple Sclerosis and NMO (Neuromyelitis Optica) disease indications planed for Q3 2019.

Arrien Pharmaceuticals competitive and unique drug discovery approaches coupled with experienced scientific and management team with expertise in multidisciplinary areas of medicinal, biological and Clinical Sciences has been the key to company's technology and success since its incorporation in 2011.

Read More..

Latest News

  • 03August
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates presenting Biocentury, The 25th Annual “News Maker in the Biotech Industry, September 7, 2018, New York City.
    Read more..

  • 05June
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates in Bio International Conference Boston, June 5-7, 2018.
    Read more..

  • 09February
    2018

    Salt Lake City:
    Arrien Pharmaceuticals Management participates in American Academy of Dermatology (AAD) Annual Meeting in San Diego, Calif., on Feb. 16-20, 2018.
    Read more..

  • 08January
    2018

    Salt Lake City:
    Arrien Pharmaceuticals management participates in 36th annual J. P. Morgan Health Care Conference | January 8-11, 2018 at the Westin in San Francisco, California, USA.
    Read more..

  • 28June
    2017

    Salt Lake City:
    Arrien Pharmaceuticals announces a worldwide license agreement for ARN-6039, a clinical stage oral ROR-?t inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders.
    Read more..

  • 21February
    2017

    Salt Lake City:
    Arrien Pharmaceuticals pleased to announce that the American Association for Cancer Research (AACR) Selection Committee has accepted the Latte-Breaking Abstract titled 'Discovery of ARN-3261 as a Potent, Selective, Orally Available SIK2 Inhibitor for Treating Ovarian, Endometrial, Primary Peritoneal, Fallopian tube, and Triple Negative Breast Cancers' for presentation at the AACR Annual Meeting 2017 to be held in Washington, DC on April 1-5, 2017.
    Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
    Session Date and Time: Wednesday Apr 5, 2017 8:00 AM - 12:00 PM
    Session Location: Poster Section 34
    Poster Number: 4
    Abstract Number: LB-296
    http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105#.WKu1gfkrJHY

  • 11January
    2017

    Salt Lake City:
    Arrien Pharmaceuticals Management to participate in 2017 AAD (American Academy of Dermatology) Annual Meeting on March 03-07, 2017 in Orlando, Florida.
    Read More..

More News

Our Pipeline

Arrien Pharmaceuticals a small molecule targeted therapeutics drug discovery and development company, working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer and CNS/Neurodegenerative diseases.

Therapeutic Areas

Multiple Cancer Indications

Arrien Pharmaceuticals is pursuing a number of drug targets for the treatment of different cancers particularly targeting protein kinases. The lead candidate belongs to a class of 3000 series Candidate Ready ARN-3261...

PsO/MS/NMO

Arrien Pharmaceutical has discovered and advanced the development of small molecule antagonists targeting Retinoic acid-related orphan nuclear receptor gt (RORgt)/RORg. RORgt is the key transcription factor and is the master...

Rheumatoid Arthritis (RA)

Arrien Pharmaceuticals is developing ARN-4079, a novel oral and highly selective irreversible kinase inhibitors selectively targeting JAK3 and ITK kinases, which play vital role in several diseases including Rheumatoid arthritis...

Parkinson's Disease (PD)

The lead candidates ARN-1104 is now advanced into pre-clinical stage of development for Parkinson's disease. ARN-1104 is a orally available small molecule possess promising neuroprotective activity and excellent DMPK/Tox profiles...

Arrien Pharmaceuticals applying its proprietary “Fragment-Field Drug Design” (FFDD) technology to identify novel, Med-Chem tractable hits into high ligand efficient leads derived from core scaffold binding patterns with in the target protein active site hot-spots